Suzhou Fengbei Biotech Stock Co., Ltd. (SHA:603334)
China · Delayed Price · Currency is CNY 51.97
-1.43 (-2.68%)
Apr 21, 2026, 3:00 PM CST
SHA:603334 Revenue
In the year 2025, Suzhou Fengbei Biotech Stock had annual revenue of 3.17B CNY with 62.77% growth. Suzhou Fengbei Biotech Stock had revenue of 919.39M in the quarter ending December 31, 2025, with 63.89% growth.
Revenue
3.17B
Revenue Growth
+62.77%
P/S Ratio
2.42
Revenue / Employee
9.22M
Employees
344
Market Cap
7.66B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.17B | 1.22B | 62.77% |
| Dec 31, 2024 | 1.95B | 220.23M | 12.75% |
| Dec 31, 2023 | 1.73B | 19.09M | 1.12% |
| Dec 31, 2022 | 1.71B | 413.11M | 31.89% |
| Dec 31, 2021 | 1.30B | 505.78M | 64.04% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Anhui Huaheng Biotechnology | 2.86B |
| Xiangxue Pharmaceutical | 1.47B |
| Nanjing Vazyme Biotech | 1.38B |
| Chengdu Kanghua Biological Products | 1.21B |
| Wuhan Keqian Biology Co.,Ltd | 949.74M |
| Acrobiosystems | 794.52M |
| GemPharmatech | 793.25M |
| Daan Gene | 765.48M |